Neuronetics
Neuronetics' revenue rose 99.2% to $149 million in fiscal 2025. Its operating margin was −21.1%, up from −46.1% a year earlier. Free cash flow was −$21 million. The diluted share count rose 107.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Neuronetics lost money in fiscal 2025: a net loss of $39 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 94 | 70 | 60 | 18 | 28 |
| Debt incl. finance leases | 35 | 36 | 59 | 55 | 66 |
| Net debt (negative means net cash) | −59 | −34 | −0 | 37 | 38 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.4x | 0.6x | 1.7x | 2.0x | 2.9x |
| Interest coverage | −6.9x | −8.3x | −5.6x | −4.7x | −3.7x |
| Current ratio | 7.3x | 3.0x | 4.7x | 1.9x | 2.0x |
| Quick ratio | 6.9x | 2.7x | 4.3x | 1.7x | 1.9x |
Cash flow
Projections
Project Neuronetics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4.8 million of Neuronetics shares on the open market, and 3 insiders sold $270,405.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Jorey Chernett10% owner | Bought | 14,000 | $3.16 | $44,240 | Form 4 |
| Jul 14, 2026 | Jorey Chernett10% owner | Bought | 35,000 | $1.78 | $62,300 | Form 4 |
| May 19, 2026 | Jorey Chernett10% owner | Bought | 100,000 | $1.17 | $117,000 | Form 4 |
| May 12, 2026 | Jorey Chernett10% owner | Bought | 475,000 | $1.34 | $636,500 | Form 4 |
| Apr 21, 2026 | Jorey Chernett10% owner | Bought | 100,000 | $1.51 | $151,000 | Form 4 |
| Apr 20, 2026 | Jorey Chernett10% owner | Bought | 100,000 | $1.58 | $158,000 | Form 4 |
| Mar 30, 2026 | Jorey Chernett10% owner | Bought | 385,442 | $1.25 | $481,802 | Form 4 |
| Mar 27, 2026 | Jorey Chernett10% owner | Bought | 500,000 | $1.35 | $675,000 | Form 4 |
| Mar 26, 2026 | Jorey Chernett10% owner | Bought | 25,000 | $1.44 | $36,000 | Form 4 |
| Mar 25, 2026 | Jorey Chernett10% owner | Bought | 125,000 | $1.40 | $175,000 | Form 4 |
| Mar 20, 2026 | Jorey Chernett10% owner | Bought | 169,472 | $1.41 | $238,956 | Form 4 |
| Mar 19, 2026 | Jorey Chernett10% owner | Bought | 450,000 | $1.33 | $598,500 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 3 of 9 | 4 of 9 |
| Rule of 40 | −38.8% | −38.4% | 85.0% |
| Altman Z'' | −7.73 | −9.80 | −10.38 |
| Accruals ratio | 1.6% | −9.9% | −13.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | 3 of 9 | 4 of 9 |
Compare
Put Neuronetics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Neuronetics | FY25 | 99.2% | −21.1% | −14.2% | −37.5% | — | 4 | |
| InfuSystem | FY25 | 6.4% | 8.3% | 16.6% | 9.6% | 0.7x | 8 | Compare |
| Xtant Medical | FY25 | 14.2% | 5.4% | 7.6% | 10.0% | −0.5x | 8 | Compare |
| Outset Medical | FY25 | 5.1% | −55.8% | −39.4% | −88.0% | — | 6 | Compare |
| OraSure Technologies | FY25 | −38.1% | −62.6% | −46.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 34 | 40 | 53 | 63 | 49 | 55 | 65 | 71 | 75 | 149 |
| Revenue growth | — | 18.1% | 30.5% | 18.7% | −21.4% | 12.3% | 17.9% | 9.4% | 5.0% | 99.2% |
| Gross profit | 28 | 31 | 40 | 47 | 38 | 44 | 50 | 52 | 54 | 72 |
| Research and development | 8 | 8 | 8 | 14 | 9 | 8 | 9 | 10 | 13 | 7 |
| Operating income | −9 | −14 | −20 | −27 | −22 | −28 | −35 | −31 | −35 | −31 |
| Net income | −11 | −16 | −24 | −29 | −28 | −31 | −37 | −30 | −44 | −39 |
| Diluted EPS (US$) | −76.95 | −86.34 | −2.69 | −1.58 | −1.46 | −1.22 | −1.38 | −1.05 | −1.38 | −0.59 |
| Diluted shares (millions) | 0 | 0 | 9 | 18 | 19 | 26 | 27 | 29 | 32 | 66 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −11 | −21 | −30 | −28 | −28 | −31 | −32 | −31 | −20 |
| Capital expenditure | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 1 |
| Free cash flow | −9 | −12 | −22 | −31 | −29 | −30 | −34 | −34 | −32 | −21 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Stock-based compensation | 0 | 0 | 2 | 3 | 4 | 8 | 9 | 7 | 6 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 17 | 29 | 105 | 76 | 49 | 94 | 70 | 60 | 18 | 28 |
| Debt incl. finance leases | — | 30 | 30 | 31 | 35 | 35 | 36 | 59 | 55 | 66 |
| Total assets | — | 39 | 117 | 100 | 79 | 141 | 117 | 116 | 141 | 142 |
| Total liabilities | — | 44 | 46 | 52 | 53 | 56 | 60 | 82 | 109 | 115 |
| Shareholders' equity | −177 | −193 | 71 | 48 | 26 | 85 | 57 | 34 | 28 | 22 |
| Margins and ratios | ||||||||||
| Gross margin | 80.7% | 76.2% | 76.4% | 75.4% | 76.5% | 78.9% | 76.3% | 72.5% | 72.3% | 48.5% |
| Operating margin | −27.3% | −33.7% | −37.6% | −43.0% | −45.3% | −49.8% | −53.9% | −42.8% | −46.1% | −21.1% |
| Net margin | −32.8% | −39.7% | −45.7% | −46.4% | −55.8% | −56.4% | −57.0% | −42.3% | −58.4% | −26.1% |
| Free cash flow margin | −25.9% | −29.0% | −40.9% | −50.0% | −59.1% | −54.9% | −52.1% | −48.2% | −43.4% | −14.2% |
| Rule of 40 (growth + FCF margin) | — | −10.9% | −10.4% | −31.2% | −80.5% | −42.5% | −34.3% | −38.8% | −38.4% | 85.0% |
| Return on capital | — | — | — | — | — | −116.1% | −113.1% | −85.5% | −53.4% | −37.5% |
| Return on equity | — | — | — | −48.9% | −74.9% | −56.4% | −52.2% | −66.2% | −141.2% | −155.7% |
| Return on assets | — | — | −30.9% | −26.8% | −30.7% | −28.4% | −28.8% | −25.9% | −34.0% | −27.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |